Tag: Cancer: Prostate

Benefits include better discrimination between risk levels

Men with negative mpMRI results avoiding biopsy did not have increased risk for clinically significant prostate cancer

Findings seen among men enrolled in one year of active surveillance

Increases seen in some countries, mostly in Africa, Asia, Latin America and the Caribbean, and Central and Eastern Europe

Lower cumulative incidence reported for two-year physician-scored toxicity and late-grade ≥2 toxicity with MRI guidance

From 2000 to 2019, definitive treatment for those with intermediate- or high-risk disease and limited life expectancy increased

12-year risk for urinary or sexual complications 7.23 and 2.76 times higher for prostatectomy, radiotherapy versus no treatment

Authors say this classification has the potential to minimize overtreatment and undertreatment

Twenty-two pesticides showed direct associations with prostate cancer incidence in discovery and replication cohorts

Higher Healthy Eating Index score linked to significantly lower risk for grade reclassification in men undergoing active surveillance